Sponsored and organized by:


WHERE INNOVATIVE LIFE SCIENCE COMPANIES

MEET INVESTORS
// Next Edition March 1st-2nd 2022// Euro-Swiss Technopole
//Archamps//France

 
BioData Overview (2002-2010)

The Forum

Every year in January since 2002, BioData brings together executives and decision

makers from leading pharmaceutical companies, innovative biotechnology

enterprises, investors and major high tech industries.
Intended for investors responsible for asset allocation in the life science sector

and financial analysts, it addressed the major issues facing the biotechnology

industry and aimed to promote the position of Switzerland in the European

Biotech Industry. You will find below the list of all the people who made the success of BioData:

- our sponsors and partners,

- the financial institutions registered,

- the companies registered in "company presentation" sessions,

- the speakers of our plenary sessions,

- and our participants, with some information on their distribution

You will also be able to read the final programme of each edition, at the very end of this page.

 

Sponsors and Partners

     

 

                 

      

  

    

 

     

 

     

  

     

 

      
     

  

 

  

           

  

  

     

     

     
     
  
     

           
     
 
     

 

 

 

   
     
                                                   
 
 
     

 

     

 

     
          

     

  

     
   
     
 
                            
 
     
      
 

Financial Institutions registered

3i Gestion

Active Advisors

Activgest

Adamant Biomedical Investments

Adcap

Aelios Finance

Affentrager & Associates

AFFIX Corporate Finance

AGF Private Equity

Aisling Capital

Akuo Investment

Alexion Ventures

AlpInvest Partners N.V

Alta Berkeley

Amorcage Rhône Alpes

Apax Partners

Aravis Partners

Arca Investment Partners

Atlas Ventures

Auriga Partners

Avance, Basel GmbH

AXA Private Equity

Banco del Gottardo

Banexi Ventures Partners

Bank Bellevue Asset Mgt

Bank Julius Baer

Bank Leu

Bank Sal. Oppenheim & Cie

Bank Sarasin

Bank Vontobel

Banque Cantonale de Genève

Banque Cantonale Vaudoise

Banque Faisal

Banque Nationale Suisse

BB Biotech Ventures

Berna Venture

BioAlps

BioArk / CimArk

BioAssociés Sarl

Biobank Technology Ventures L

BioFund

BioGestion-Fonds Bioam

Biomed Invest

Bionest Partners

Biosafe

BNP Paribas

Bordier & Cie

Breslin Biotech

Brilleon Capital

Bryan, Garnier & Co

BSI

BT&T Group

BZ Bank

Canaccord Capital

Capital Group Companies

CDC Entreprises FP Gestion

CDC Entreprises Innovation

CEA Investissement

Chandra Capital

CIC

CITCO

Citigroup

Clariden

CMG Capital

CNCE

Coges

Cowen & Company

Creadvise

Crédit Agricole Cheuvreux

Credit Agricole Private Equity

Crédit Lyonnais

Crédit Suisse

Cukierman & Co Life Sciences

Daiwa Securities

De Pury Pictet Turrettini & Cie

Defi Gestion

Deka Investment

Developement Economic Western Switzerland

Deviris Pharma

Dimension Corporate Finance

Dresdner Bank

Eclosion

Edmond de Rotshild Investment Partners

EFG Bank

EIM SA

Endeavours

Entrepreneurs Fund

Equinet

ERAI

E-Synergy

Euronext

Europa Partners

European Ventures Partners

Euthemis

Ferrier Lullin & Cie

Floralis

Florham Consulting SA

Fonds Européen d'Investissement

Freelancer

Gedefi Asset Management SA

Genevest Consulting group

Global Biomedical Partners

Global Life Science Ventures

Goldmann Sachs

Hapoalim Securities USA, Inc.

HBM BioVentures

HealthCap

Healthios Inc.

Helvea

Himalaya Capital Partners

IMSF International

Index Ventures

Inventages Venture Capital

Invest in Western France

JP Morgan

Kepler Equities

Kurma Biofund

Landsbanki Kepler

Laverda Limited

Lombard Odier Darier Hentsch &  Cie

Matignon Investissement et Gestion

 

 

MDL Finance

Medicines For Malaria Ventures

Medinsight

Merieux Developpement

Merrill Lynch

Morgan Stanley

NeoMed

New England Partners

Nipralabs Investment Management

NMT

Nomura

Novartis Venture Fund

NWI

NYSE Euronext

NZB Neue Zürcher Bank

Oddo AM

Omega Advisors

Orbimed Advisors

OSEO

Oxford BioScience Partners

Panmure Gordon

Pantheon Ventures

PAR Finance

Paul Capital Partners

Pictet & Cie

PricewaterhouseCoopers

Private Bank Switzerland

Privateq Advisors AG

Renaissance

Richefield Partners Ltd

Robert Frazer Finance

Rodman & Renshaw

Royal Bank of Canada

Sectoral Asset Management

SG Cowen

Siparex

SME BioAdvisor

Sofinnova

Soyco Capital Management

Swiss Re

Swissfirst Bank

Swiss National Bank

SWX

Talentmark

ThinkEquity

Tilocor International S.A.

Truffle Venture

Turenne Capital

TVM

UBS

Unicorn Bio Tutors

Union Bancaire Privée

Venture Incubator

Vespucci Capital

VI Partners AG

Vinci Capital

Vision Capital

Wealth Management Advisors

WestLB Panmure

Widmann Associates

Wolf Research & Asset Mgt

Company Presentations registered

 

ABMI,

3-dimensional Pharma

AC Immune,

Actelion,

Addex Pharmaceuticals,

Affymetrix Inc,

AGCom Biotech

Agy,

Alkermes,

Alpes Laser,

Alizé Pharma,

Amgen,

Anaconda Pharma,

Anavex,

Animascope,

Anergis,

Antagene,

Anteis,

Apoxis,

Aptanomics,

ArisGen,

Arpida,

Arrayon Biotechnology,

Athelas,

Atheris Laboratoires,

Atugen,

Aureus Pharma,

Avesthagen,

AVI BioPharma,

AXS Medical,

Axovan,

Basilea Pharmaceutical,

Berna Biotech,

Bio3 Research,

BioAlliance Pharma,

Biocell Interface,

Biocortech,

BioIT,

BioMatech,

Biomedix,

Biomethodes,

Biom’up,

Bioresearch & Partners,

Bioring,

Biosafetys,

Bioscan,

Biosensors International,

Biovitrum,

Bioxell,

BrukerDaltonics,

CardialCare,

caT,

Cellpep,

Cellmade

Cellular Dynamics International,

CeNeS,

Cerebel

Cerep,

Cerma,

Chienna,

Chronix Biomedical,

Clearant,

CMS Laboratory,

Cogenics-Genome Express

CoreValve,

Crucell,

Cyclacel,

Cypress Biosciences,

Cytheris

Cytokinetics,

Cytomics,

Cytos biotechnology,

DataMining International,

Debiopharm,

Dermadis,

 

Diagnoplex,

Diagnoswiss,

Dictagene,

Drug Design Technologies,

Elana BV ,

EndoArt,

Endosense,

Erytech Pharma,

Etna Biotechnology,

ESBAtech,

Euroscreen,

Evolva,

ExcellGene,

Frimorfo,

Gene Control,

GeneData,

Gene-IT,

GeneProt,

Genetic Immunity,

Genetronics,

GeNeuro,

Geninex,

Genionics,

Genkyotex,

Genmab,

Genome Express,

Genomic,

Genomining,

Genopoïetic,

Genostar,

Genoway,

Glycart Biotechnology,

Graffinity Pharma,

HC Forum,

Heidelberg Pharma,

Hewlett-Packard,

Hybrigenics,

ID Biomedical,

IDEC Pharmaceuticals,

Idenix Pharmaceuticals,

IDM,

IMI Intelligent Medical Implant,

Immun ID,

Ingenium Pharmaceuticals,

Innate Pharma,

Innogenetics,

Integragen,

Intercell,

Intercytex

IsoTis OrthoBiologics,

Kalys,

Kikamedical,

Koelis,

Kuros Biosurgery,

LAB International,

LemanCardioVasculaire,

Lemnagene,

Lexicon Genetics,

Libragen,

LifeScience-Consulting,

LION Bioscience,

LonzaGroup,

Med Discovery,

Medical Device Works

Medicure,

MediGene,

Medion Diagnostics,

Medipol,

Medtronic,

Mellitech,

Merck-Serono,

Meristem,

Micromet,

MillenniumPharmaceuticals,

ModexTherapeutics,

 

 

 

 

 

Molecular Partners,

Morphochem,

Mondobiotech,

Morphosys,

Mutabilis,

Myocontract,

NanoInk,

Narval,

Neurotech,

Nicox,

Nikem Research,

Nitec Pharma,

Noraker,

Novocib,

NovImmune,

Novirio,

Nucleis,

ObeTherapy Biotechnology,

OM Pharma,

OptiScan Biomedical, Inc.,

OrganiTech,

Orthovita,

Otologics,

Oxford Immunotec,

Oxyclar,

Paion,

PharMida AG,

Pharmos,

Photo Derma,

Phytopharm plc,

Picometrics,

Promethera Biosciences,

Protein'Expert,

Platform Computing,

Plethora Solutions,

Praxim,

PreenTec,

Prionics,

Protein'eXpert,

Qiagen,

Quantonix,

Selexis,

Serono International,

Seyonic,

Sinclair Pharma,

SIRO Clinpharm,

Sleepinnov Technology,

Sloning Biotechnology,

Smartbead,

Smartcanula,

Sonoscope,

Speedel,

Spinomix,

StereoTools,

Stressgen Biotech,

Stryker,

Suriasis,

Swiss Institute of Bioinformatics,

Swiss Medical Care,

Tecan,

The Genetics Company,

Themis-Icta Group,

Tigenix,

Transgene,

Trigen,

TriReme Medical,

Unilabs,

Vital-IT

Vivalis,

Voxcan,

World of Medicine,

Xcelens,

Xigen,

XLBiosim,

Xytis Pharmaceuticals,

Zealand Pharma.

 

 

 

Speakers

Bernard Accoyer, President of the French National Assembly, and Mayor of Annecy-Le-Vieux

Patrick Aebischer, President, Ecole Polytechnique Fédérale de Lausanne, EPFL

Domenico Alexakis, Executive Director, Swiss Biotech Association

Gilles Amsellem, COO,Avesthagen

Valérie Ayache, General Manager, Adebag

Martin Bachmann, Executive Vice President & Chief Scientific Officer, Cytos

Amos Bairoch, Professor, Swiss Institute of Bioinformatics

Daniel Balmisse, Deputy COO, CDC Entreprises FP Gestion,

Jean-Luc Balzer, Directeur Industrial Development and Programs, Cancéropole

Jack Barbut, CEO, NovImmune

Alim Benabid , Professor, Director of U318 INSERM, Grenoble University

Ariel Beresniak , CEO, Data Mining International

Joël Besse , Senior Principal, Atlas Venture LLP

Ali Bhojani, Managing Director, Canaccord

Kim Bill, Vice President Business Developement and Licensing, Debiopharm

Lionel Binns, Corporate Manager, Life Sciences, Compaq

Bill Blake, Vice President, High Performance Computing Worldwide, Compaq

Friederich von Bohlen, CEO, LION bioscience AG

Jean-Yves Bonnefoy, Managing Director, Canceropôle Lyon-Rhône-Alpes

Allistair Booth, Partner, Fasken Martineau

Anne-Sophie Borgeaud, Vice President, Fund Manager Life Sciences, Lombard Odier Darier Hentsch

Benoit Bouche, Head of Corporate Finance, Kepler Equities

Stéphane Boudon, Chairman, CDC Ixis Innovation

Herve Bourlard, Dalle Molle Institute for Perceptual Artificial Intelligence

Richard Borgi, Strategy Consultant-medical device, Bri

Gilles Brisson, President of Management Board, Aventis

Ronald Bronsaer, CellMade, CEO

Shaun Brown, Director, Innovator Capital Limited

Kai Brüning, Senior Portfolio Manager, Deka Investment

Philippe Bulet, BioPark Porte Sud de Genève , Operational manager

Jean-Philippe Burcklen, Head of Venture Capital Operations, European Investment Fund

Leon Bushara, VP, Head of Business Development, Serono

Stefan Catsicas, EPFL Professor, Chairman, Tilocor International

Laurence Cassarino, Equity Analyst-Pharmaceuticals, CDC IXIS Securities

Fabio Cavalli, CEO, MondoBiotech

Jérôme Chanton, Fund Manager, Life Sciences, Lombard Odier Darier Hentsch,

Daniel Christiaen, Business Development Manager, Rhône- Alpes Genopole

Philippe Cinquin, Head of Medical Informatics, University of Grenoble

Anne-Marie Comparini, President, Rhone-Alpes Region

Fabrizio Conicella , Business Development Manager, Bio-Industry Park Canavese

François Conquet, Early Stage Licensing Director, Merck Serono

Peter B. Corr , Senior Vice President, Science and Technology, Pfizer Inc.

Jean-Yves le Cotonnec, Chief Executive Officer, Triskel

Didier Cowling, CEO, Kuros

Thomas Cueni, Secretary General, Interpharma

Zubin Dastoor, Senior Financial Analyst, NZB Neue Zürcher Bank

Michel David, Vice President and General Manager, Clearant Europe

David Deperthes, Dermadis, CEO

Francesco De Rubertis, Partner, Index Ventures

Frederic Desdouits , Managing Partner, Bionest Partners

Zlatko Dimcovski, CEO, BioScan

Philippe Dro, CEO, EndoArt

Bill Drohan, President, Clearant

Benoît Dubuis, Head of School of Life Sciences , EPFL

Tim Dyer, Chief Financial Officer, Addex Pharmaceuticals

Juerg Eckhardt, Senior Investment Manager, Global Life Sciences Ventures

Fouad Elbaroudi, CEO, AXS Medical

Ivor Elrifi Co-chair of the Intellectual Property Section,Mintz Levin

Andreas Emmenegger, CFO, Glycart Biotechnology

Lionel Eperon, President, BioAlps

Jacques Essinger, Executive Chairman, Symetis

Boi Faltings, Ecole Polytechnique Fédérale de Lausanne, EPFL

Sam Fazelli, Senior Biotechnology Analyst, Nomura

Raimund Gabriel, Partner, MC Services

Andrew Galazka, Senior VP Autoimmune and Emerging Therapeutic Areas, Merck Serono

Jesus Martin Garcia, Founder and Managing Partner, Eclosion

Alexandre Gauthier-Jacques, Associate Director, UBS

Manuel Gea, Vice President, Biotech Committee, LEEM

Dominique Gillot ,Life Science manager Europe, Middle East and Africa (EMEA), Hewlett-Packard

Reinhard Glück, CSO, Berna Biotech

Thomas Goebel , PhD, Principal, Neomed Management

Jaap Goudsmit, CSO, Crucell

Vincent Grandjean, Chancellor of the Canton of Vaud

Christophe Gretler, Director Equity Research, Credit Suisse First Boston

Jennifer Griffiths Director, Global Business Development, Novartis Pharmaceuticals

Yvonne Gunsch-Wegmann, VP Head of Issuer and Investor Relations, SWX

Claudia Gutjahr-Loeser, Senior Director, Head of Corporate Communications and Investor Relations, Morphosys

Christopher Haig, VP Mktg, Bus Dev, Intl sales, TriReme Medical

Eric Halioua, Senior Manager, Arthur D. Little

Denis Harran , General Agent, La Suisse Assurances

Harry Heinzelmann, Scientific Advisor, NanoDimension

Patrick Henri, Senior Vice President Marketing & Business Development, Surgetics Network

Denis Hochstrasser , Head of the Department of Pathology, University Hospital of Geneva

Bob Holland, Archamps Technopole, Research and Training Projects Manager

Joost Holleman, Principal Fund Investments, AlpInvest Partners

Olfa Hooft, General Manager, FFSRT

Jeffrey Hubbel, Professor in the Integrative Biosciences Institute for Chemical Sciences and Technology, Swiss Federal Institute of Technology

Alice Huxley, CEO, Speedel

Samuel D. Isaly, Managing Partner, Orbimed advisers

Alan Jakimo, Partner, Sidley Austin Brown & Wood LLP

Victor Jongeneel ,Director, Vital-IT Centre

Kuno Jung, Investement Manager, Global Life Science Ventures

Carole A.Jones, Consultant and Pratice Area Leader, IMS global Consulting

Daniel Kahn, International Lawyer, Kahn & Associés

Nadia Kamal, Deputy Managor, Crealys

Tom Kass, Fund Manager, EFG Bank

Ann Kato, Professor, Department of Neuroscience, University of Geneva

Ulrich Kinzel, Director, Corporate Finance, Nomura Code Securities Limited

Hervé de Kergrohen , Chairman, Biodata

Yigal Koltin , VP, Alliance Development, Millennium Pharmaceuticals

Herbert Köntges , Chief Business Officer, Medical Device Works

Jay Kranzler, CEO,Cypress Bioscience Inc

Thane Kreiner, Senior Vice President, Corporate Affairs, Affymetrix

Ivan Kugener, Senior Vice President, Deputy Director specialized Fund Management, Lombard Odier Darier Hentsch

Robert Kuster , Chief economic development advisor , State of Geneva

Carlo Lamprecht, Minister of Economic Affairs, State of Geneva

Christophe Lamps , Partner, Rochat & Partners

Thierry Laugel, Managing Partner, Kurmabiofund

Stéphane Lavallée, CEO, PraximMedivision

Corinne Lebourgeois, Managing Director, Med C Partners

Philippe Le Goff, Dr. Ing., General Manager, H&LG Consultants SARL

Bernard Lemaître, CEO, Stedim

Bruno Levy, President, Strategyn

Cedric Loiret-Bernal , CEO, Vespucci Capital

David Loucks, CEO, Healthios

Giampiero de Luca, Chief Intellectual Property Counsel, Serono International

Jean-Charles Magnin, Director Economic Affairs, Economy and Health Department

Nathanaël Mauclair, Deputy Director – International Listings, Euronext

Jacqueline Maurer- Mayor, Minister of Economy, State of Vaud

Andrew McDonald , Research Analyst, ThinkEquity Partners

Jean-Claude Manini, Senior economist for Europe , The Conference Board

Georges-David Medina, Funding Partner, Hinvest Partners

Eric Menotti, Fund Manager, Lombard Odier Darier Hentsch & Cie

Juerg Meyer, Executive Director, Novartis Venture Fund

Michael Meyers , Managing Director and Partner of Global Biomedical Partners Ltd

Stefanie M. Monge, Senior Associate, Poledna Boss Kurer

Bruno Montanari, Investment Manager, Credit Agricole Private Equity

Geneviève Morand , Founder and CEO, Rezonnace.ch

Simon Moroney, CEO, Morphosys

Villoo Morawala Patell ,Founder & CEO,Avesthagen

Cédric Moreau, Analyst, Bryan, Garnier & Co

Simon Moroney, CEO, Morphosys

Michel Morre, CEO, Cytheris

André Mueller, Member of the Board of Directors, former CFO,Actelion

Alexandre Müller, Senior Consultant, Dynamics Group

Patrick Nef, CSO & VP Business Development, Xytis Pharmaceuticals

Sandor Nemeth, Partner/Attorney, Szecskay Attorney's at Law

Claudio Nessi, Partner, Neomed

Gilles Nobécourt, Partner, Edmond de Rothschild Investment Partners, Life Sciences Team

Matthias Nordmann, Attorney/Partner, SKW Schwarz

René Nordmann, CEO, Medinsight

Isabelle Nutall, Programme Manager, WHO

Markus Ochs ,Director,Stryker

B. Oesch, CEO, Prionics

Robbin Offord, Professor,Faculty of Science & Medicine, University of Geneva , Chaiman Eclosion

Othmar Pfannes , CEO, Genedata

Antoine Papiernik , General Partner, Sofinnova

Chantal Parpex, President, CDC Entreprises Innovation

Roland Pascal, President of Archamps Technopole

Eric Perouse, Manager France, Perouse

Damian Pethica, European Biotech Analyst, JP Morgan

Maurizio PetitBon, Director, European Venture Partners

Andrea Pfeifer, CEO, AC Immune

Bob Pooler, Senior Research Analyst - Pharmaceuticals Lombard Odier Darier Hentsch

Sebastien Putallaz , Vice President, Global Biomedical Partners

Irene Püttner, Fund Manager HealthSar, Bank Sarasin

Serge Raicher, Partner, Pantheon Ventures

Andrea Rappagliosi, Vice President, Health Policy Governments Relations, Merck Serono

Holger Reithinger, Principal, Global Life Science Ventures

Wolfgang Renner, CEO, Cytos Biotechnology

Christophe Renondin, Partner, CDC Entreprises Innovation

Christophe Reymond , COO, Anergis

Arthur Roach, Head of Neurobiology, Serono Pharmaceutical Research Insitute

Subhasis Roy, Director, Landsbanki Kepler

Francisco Rubio-Sandi, CEO, Geninex

Bogdan von Rueckmann, Partner, Inventages Venture Capital

Peter Rule, Chairman and CEO, Optiscan BioMedical   

Odile Rundquist, Pharmaceutical & Biotech Analyst – Equity Brokerage, Vontobel

Aymeric Sallin, Founder and Managing Partner, NanoDimension

William Saurin , CEO, Genomining

Jean-Alain Schulz, Patent Attorney, Bugnion SA

Maarten Schutt, Attorney at law, Kennedy Van der Laan

Raghuram Selvaraju, Head of Healthcare Research, Hapoalim Securities USA

Allan L.Shaw, CFO, Serono International

David Sherwood, Vice President Quality Assurance, Lonza Biologics plc

Francesco Sinigaglia, CEO, BioXell

Michael Sjöström, CFA, Founder and Chief Investment Officer, Sectoral Asset Management

Philippe Sordet, President, BioAlps

Daniel Steck, Healthcare Analyst, Lombard Odier Darier Hentsch & Cie

Gilles Talobotier, General Manager, GRAIN

Tangui Maurice, Consultant, Amylgen

Arthur Thomas, Business Developpement, Vital-IT

François Thomas , Venture Partner, Atlas Ventures

Larissa Thomas , European Biotech Analyst, Canaccord

Simon Thompson, Group Director, Publications, IMS

Werner Tschollar, CEO , Xytis

Pierre-François Unger, President of the Geneva State Government and Minister in charge of the Economy and Health

Hans Van Swaay, Head of Private Equity, Pictet & Cie

Suren Vardanian, Director General, Moscow Agency for Export and Investment Promotion

Michel Venanzi , Fund Manager Life Sciences, Vice President, Lombard Odier Darier Hentsch & Cie

Roger Vioud , Chairman, International Commission of the Regional Council of Rhône Alpes

Marc Vollenweider, CEO, Evalueserve

Madeleine von Holtzen, Journalist and Partner, Bontron & Co

Lutz Weber, Chief Executive Officer, Morphochem

Dinah Weissmann, CEO, Biocortech

Tim Wells, Vice President, Head of discovery, Serono International

Barry Wilson , President, Medtronic International

Peter Wullschleger, Head Investor Relations, Givaudan Suisse SA

Robert Wyss , Head of Market Development Division, SWX

Robin Young, Managing Director, HealthpointCapital

Olav Zilian, Research Analyst – Pharma & Biotech, Helvea

 

The Participants


· More than 2700 delegates
· More than 230 speakers
· More than 300 company presentations

The Audience


· 40% from the investors community
· 50% from the biotech-medtech and pharmaceutical sector
· 20% from high tech support industries and service companies

Geographic Distribution of the Audience


· 50% from Switzerland
· 30% from the EU
· 20% from North America, India, Japan, Australia...

Programme Highlights

. BioData2002

. BioData2003

. BioData2004

BioData2005

BioData2006

BioData2007

BioData2008

  BioData2010